MedPath

How does oxytocin affect brain functioning in people at high risk of developing psychosis?

Not Applicable
Completed
Conditions
Schizophrenia, schizotypal and delusional disorders
Mental and Behavioural Disorders
Registration Number
ISRCTN48799530
Lead Sponsor
King's College London
Brief Summary

2020 Other publications in https://pubmed.ncbi.nlm.nih.gov/32655132/ Intranasal oxytocin increases heart-rate variability in men at clinical high risk for psychosis: a proof-of-concept study (added 15/03/2023) 2019 Results article in https://pubmed.ncbi.nlm.nih.gov/30626906/ Oxytocin modulates hippocampal perfusion (added 15/03/2023) 2020 Results article in https://pubmed.ncbi.nlm.nih.gov/32572020/ Oxytocin on brain activation during inferring others’ beliefs and social emotions (added 15/03/2023) 2019 Results article in https://pubmed.ncbi.nlm.nih.gov/30928180/ Oxytocin on glutamate and other metabolites (added 15/03/2023)

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Male
Target Recruitment
30
Inclusion Criteria

Among the new referrals to the OASIS service, South London and Maudsley NHS Foundation Trust, we will enroll those meeting inclusion criteria for a UHR state for psychosis (as defined on the CAARMS revised version questionnaire).

Exclusion Criteria

1. Personal history of psychotic illness (i.e. schizophrenia, schizoaffective disorder or related psychosis)
2. Aged below 18 years old
3. Aged over 35 years old
4. Significant cognitive deficit (IQ<60 as measured by the shortened WAIS)
5. Significant history of drug or alcohol misuse or dependence
6. Severe neurological and medical conditions
7. Evidence of hyponatremia in participant's recent blood test
8. Rejection of informed consent
9. Pregnancy (apply to women of childbearing age)
10. Breastfeeding (applies to women of childbearing age)
11. Non-use of contraceptive methods (apply to women of childbearing age).

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Regional brain response to oxytocin versus placebo challenge in subjects at ultra-high risk (UHR) for psychosis measured using MRI, which includes fMRI tasks of social cognition and other neuroimaging readouts (arterial spin labelling, resting-state fMRI, and MR-spectroscopy), during the challenge
Secondary Outcome Measures
NameTimeMethod
The are no secondary outcome measures
© Copyright 2025. All Rights Reserved by MedPath